KIT and gastrointestinal stromal tumor: Whether increased neoepitopes production and this “immune hot” profile may indeed account for the relatively favorable patient outcomes of PDGFRA-driven compared to KIT-mutated GIST remains an intriguing hypothesis deserving further investigations.